IndustryRx

We estimate there's a 100% chance this podcast is looking for guests- reach out and make your move!

Topic Category:

Business

Where to Listen:

Language:

English

Copyright Notice:

Swas G.

Podcast Stats:

Number of Episodes: 1

Series Type: episodic

Content Type: AUDIO

Podcast Description

This show interviews top leaders and minds from the pharmaceutical and biotech industry.

Podcast Insights

Content Themes

The podcast focuses on pharmaceutical advancements, biotechnology innovations, and industry leadership, with specific episodes examining the development of radiopharmaceuticals, the impact of regulatory changes, and future trends in personalized medicine.

Further Podcast insights, such as show format, guest types, ideal guests, and target audience are available to Podcast Collab Club Members!

IndustryRx

This show interviews top leaders and minds from the pharmaceutical and biotech industry.

Meet Dr. Vijay Kulangara, the Director of Research and Development at Jubilant Radiopharma in Montreal, Canada. Dr. Kulangara has been leading the charge in the development of diagnostic cold kits and therapeutic radiopharmaceutical products since 2017, guiding a talented team of over 20 scientists. He holds a doctorate in synthetic organic chemistry and has a proven track record in leading teams across R&D, discovery research and technology transfer.

Join as we discuss the industry's present and future, along with his journey!

Vijay Kulangara: Director R&D, 15+ Patents, 25+ Publications and more!

Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.

For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.